Modality
Peptide
MOA
SOS1i
Target
Aβ
Pathway
Amyloid
LN
Development Pipeline
Preclinical
~Aug 2014
→ ~Nov 2015
Phase 1
~Feb 2016
→ ~May 2017
Phase 2
Aug 2017
→ Aug 2026
Phase 2Current
NCT04487703
2,579 pts·LN
2022-10→2026-06·Not yet recruiting
NCT07715788
87 pts·LN
2017-08→2026-08·Completed
2,666 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-06-082mo awayPh2 Data· LN
2026-08-134mo awayPh2 Data· LN
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P2
Complet…
P2
Not yet…
Catalysts
Ph2 Data
2026-06-08 · 2mo away
LN
Ph2 Data
2026-08-13 · 4mo away
LN
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04487703 | Phase 2 | LN | Not yet recr... | 2579 | EFS |
| NCT07715788 | Phase 2 | LN | Completed | 87 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-2901 | Pfizer | Phase 2 | AHR | |
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 |